USMLE Step 2 Quiz
Practice Cardiovascular Risk And Prevention in USMLE Step 2 with focused quiz questions that help you check what you know, review explanations, and build confidence with test-style prompts.
Question 1 / 20
0 of 20 answered
A 27-year-old man with obesity (BMI 33 kg/m²) and smoking presents for BP recheck. He smokes 15 cigarettes/day and reports high stress and minimal exercise. BP is 150/94 mm Hg. Labs: LDL 118 mg/dL, HDL 37 mg/dL, triglycerides 200 mg/dL, fasting glucose 102 mg/dL. He is not on medications. Family history is negative for early CAD. He asks whether vaping or “cutting down” is enough.
What preventive measure should be prioritized for this patient?
This quiz focuses on Cardiovascular Risk And Prevention, giving you a quick way to practice the rules, question types, and explanations that matter most for USMLE Step 2.
Try each quiz question before looking at the correct answer. Use the explanations to review missed ideas, then come back to similar questions until the pattern feels familiar.
A 27-year-old man with obesity (BMI 33 kg/m²) and smoking presents for BP recheck. He smokes 15 cigarettes/day and reports high stress and minimal exercise. BP is 150/94 mm Hg. Labs: LDL 118 mg/dL, HDL 37 mg/dL, triglycerides 200 mg/dL, fasting glucose 102 mg/dL. He is not on medications. Family history is negative for early CAD. He asks whether vaping or “cutting down” is enough.
What preventive measure should be prioritized for this patient?
Explanation: This question tests cardiovascular risk and prevention for USMLE Step 2 CK, specifically understanding smoking cessation in young adults. Cardiovascular risk management involves addressing smoking as a top priority. In the vignette, the patient's smoking, obesity, hypertension, and lipids highlight cessation needs. The correct answer, 'Recommend complete smoking cessation with counseling,' aligns with guidelines over alternatives like vaping. Choice A, switching to vaping, is not safer long-term. To help students: Discuss cessation resources, assess dependence, and debunk reduced-harm myths.
A 58-year-old postmenopausal woman with type 2 diabetes mellitus presents for routine care. She takes metformin 1000 mg twice daily and reports excellent adherence; home glucose logs are generally 90–130 mg/dL. She is sedentary due to an office job and knee discomfort, and she eats most meals from takeout. She does not smoke and drinks wine socially. BP is 136/82 mm Hg; BMI 29 kg/m². Recent labs: A1c 6.6%, total cholesterol 212 mg/dL, LDL 128 mg/dL, HDL 44 mg/dL, triglycerides 180 mg/dL, creatinine 0.9 mg/dL, urine albumin/creatinine ratio 18 mg/g. She is not taking a statin because she “feels fine.” Family history includes her mother having a fatal MI at age 54 and a maternal uncle with coronary bypass surgery in his 50s. She asks which medication change best lowers her risk of heart attack and stroke.
Which medication adjustment is most indicated based on the patient's profile?
Explanation: This question tests cardiovascular risk and prevention for USMLE Step 2 CK, specifically understanding risk assessment and preventive strategies in diabetic patients. Cardiovascular risk management involves assessing risk factors like diabetes, hypertension, dyslipidemia, and sedentary lifestyle, with preventive strategies prioritizing statin therapy for high-risk individuals. In the vignette, the patient's type 2 diabetes, elevated LDL, family history of premature CAD, and other risks warrant aggressive lipid management. The correct answer, 'Start moderate- to high-intensity statin therapy,' aligns with guidelines recommending statins for adults aged 40-75 with diabetes to reduce ASCVD events. Choice C, starting daily aspirin regardless of bleeding risk, is inappropriate as aspirin for primary prevention in diabetes is individualized and not automatic. To help students: Focus on ACC/AHA cholesterol guidelines for diabetics, differentiate primary vs. secondary prevention, and avoid overusing aspirin without risk-benefit assessment. Practice identifying statin intensity levels and indications.
A 61-year-old postmenopausal woman with type 2 diabetes presents for follow-up. She is adherent to metformin; A1c is 6.6%. She is sedentary and has BMI 29 kg/m². BP is 130/78 mm Hg. Lipids: LDL 116 mg/dL, HDL 45 mg/dL, triglycerides 165 mg/dL. She is not on lipid-lowering therapy. Family history includes mother with MI at 55. She asks which medication adjustment most reduces cardiovascular risk.
Which medication adjustment is most indicated based on the patient's profile?
Explanation: This question tests cardiovascular risk and prevention for USMLE Step 2 CK, specifically understanding lipid management in diabetic patients with additional risk factors. Cardiovascular risk management involves evaluating ASCVD risk in diabetics, where guidelines recommend statin therapy for those aged 40-75 to reduce events, alongside lifestyle modifications. In the vignette, the patient's type 2 diabetes, postmenopausal status, family history of early MI, sedentary lifestyle, and elevated LDL indicate a high risk, warranting pharmacologic intervention despite controlled A1c and blood pressure. The correct answer, 'Start moderate- to high-intensity statin therapy,' is most indicated as it directly targets LDL reduction and is first-line for cardiovascular risk reduction in this profile per ACC/AHA guidelines. Choice B, starting fenofibrate, is incorrect because it is not primary for LDL management and is typically used for severe hypertriglyceridemia. To help students: Focus on memorizing statin indications in diabetes, including risk enhancers like family history, and avoid common pitfalls such as prioritizing therapies like niacin that have limited evidence. Practice integrating patient profiles with guidelines to select evidence-based adjustments over unnecessary changes like stopping effective medications.
A 28-year-old woman presents for a pre-employment physical. She has obesity (BMI 34 kg/m²) and smokes 8 cigarettes/day. She reports high job stress and sleeps 5 hours/night. BP is 142/90 mm Hg (repeat 140/88). Labs: total cholesterol 182 mg/dL, LDL 110 mg/dL, HDL 39 mg/dL, triglycerides 170 mg/dL, fasting glucose 99 mg/dL. She takes no medications. Family history: father had hypertension; no early CAD. She asks which recommendation would most reduce her cardiovascular risk.
What preventive measure should be prioritized for this patient?
Explanation: This question tests cardiovascular risk and prevention for USMLE Step 2 CK, specifically understanding risk reduction in young adults. Cardiovascular risk management involves assessing smoking, obesity, and hypertension, with preventive strategies prioritizing cessation. In the vignette, the patient's smoking, obesity, stress, and BP elevate long-term risk. The correct answer, 'Recommend smoking cessation with pharmacotherapy options,' aligns with guidelines for comprehensive support to quit. Choice A, starting aspirin, is not indicated for primary prevention here. To help students: Discuss cessation pharmacotherapy, assess readiness to quit, and calculate lifetime vs. 10-year risk.
A 29-year-old man presents for an annual exam. He has obesity (BMI 35 kg/m²) and smokes 1 pack/day since age 19. He works a high-stress job with frequent late nights and eats mostly convenience foods. Over the past 6 months, workplace screenings show rising BP; today it is 146/92 mm Hg (repeat 144/90). He has no known chronic diseases and takes no medications. Labs: total cholesterol 198 mg/dL, LDL 122 mg/dL, HDL 36 mg/dL, triglycerides 190 mg/dL, fasting glucose 104 mg/dL. He is considering lifestyle changes but is unsure where to start. His father has hypertension; no known premature coronary disease. He asks what single change would most reduce his long-term cardiovascular risk.
What preventive measure should be prioritized for this patient?
Explanation: This question tests cardiovascular risk and prevention for USMLE Step 2 CK, specifically understanding modifiable risk factors in young adults. Cardiovascular risk management involves assessing factors like smoking, obesity, hypertension, and dyslipidemia, with preventive strategies emphasizing smoking cessation as a high-impact intervention. In the vignette, the patient's smoking history, obesity, elevated BP, and dyslipidemia significantly elevate long-term ASCVD risk. The correct answer, 'Recommend complete smoking cessation with support,' aligns with guidelines prioritizing smoking cessation to dramatically reduce CV events. Choice E, starting aspirin immediately, is not indicated for primary prevention in this low short-term risk young adult due to bleeding risks. To help students: Highlight the multiplicative effect of smoking on other risks, review cessation aids like varenicline or counseling, and understand when advanced imaging like CT angiography is unnecessary.
A 52-year-old man with type 2 diabetes for the past 8 years presents for a routine visit. He has no other medical problems and has no history of cardiovascular disease. His A1c is 7.2%, and his LDL cholesterol is 120 mg/dL. His 10-year ASCVD risk is calculated to be 8%.
According to current guidelines, which of the following is the most appropriate management for his dyslipidemia?
Explanation: Guidelines recommend that all patients with diabetes mellitus aged 40 to 75 years should be treated with at least a moderate-intensity statin, regardless of their baseline LDL cholesterol or calculated 10-year ASCVD risk. High-intensity statin therapy is recommended for diabetic patients with a higher ASCVD risk (≥20%) or multiple ASCVD risk factors. Since this patient's risk is 8%, a moderate-intensity statin (e.g., atorvastatin 10-20 mg, rosuvastatin 5-10 mg) is the most appropriate initial choice.
A 55-year-old man comes to your office for a routine health maintenance visit. He has a history of hypertension, which is well-controlled on lisinopril. He has no other medical problems and feels well. His father had a myocardial infarction at age 52. The patient does not smoke and drinks alcohol socially. His blood pressure is 132/84 mmHg, and his BMI is 28 kg/m². His non-fasting lipid panel shows a total cholesterol of 210 mg/dL and HDL cholesterol of 45 mg/dL. He has never had his cardiovascular risk formally assessed.
Which of the following is the most appropriate next step to guide the initiation of lipid-lowering therapy?
Explanation: The most appropriate next step for this patient is to calculate his 10-year risk of atherosclerotic cardiovascular disease (ASCVD) using the Pooled Cohort Equations. This calculation incorporates age, sex, race, cholesterol levels, blood pressure, smoking status, and diabetes status to estimate the 10-year risk of a major cardiovascular event. The result of this risk assessment is crucial for guiding decisions about primary prevention, including the initiation and intensity of statin therapy. For adults aged 40-75, this is the first step before deciding on treatment.
A 62-year-old woman with a 10-year history of type 2 diabetes mellitus and hypertension presents for follow-up. Her medications include metformin, lisinopril, and amlodipine. She does not smoke. Her blood pressure is 138/88 mmHg. A recent lipid panel shows an LDL cholesterol of 125 mg/dL. Her calculated 10-year ASCVD risk is 22%.
Which of the following is the most appropriate initial therapy for this patient's dyslipidemia?
Explanation: This patient has multiple risk factors including type 2 diabetes and hypertension, and her calculated 10-year ASCVD risk is >20%, placing her in the high-risk category for a primary prevention. According to current guidelines, patients at high risk should be started on high-intensity statin therapy. High-intensity statins include atorvastatin 40-80 mg or rosuvastatin 20-40 mg. Therefore, initiating atorvastatin 40 mg is the most appropriate choice. Rosuvastatin 10 mg is a moderate-intensity statin.
A 48-year-old woman is newly diagnosed with stage 1 hypertension (BP 135/85 mmHg) and dyslipidemia. Her BMI is 32 kg/m². She is motivated to make lifestyle changes to improve her health. You discuss several options with her.
In addition to initiating pharmacotherapy, which of the following single lifestyle modifications will likely have the greatest impact on lowering her blood pressure?
Explanation: While all listed options are beneficial for blood pressure control, weight loss has the most significant effect. On average, blood pressure is reduced by approximately 1 mmHg for every 1 kg of weight loss. A 10 kg weight loss can lead to a 5-10 mmHg reduction in systolic blood pressure. The DASH diet can lower SBP by about 11 mmHg, but achieving this requires significant dietary changes. Sodium restriction and exercise have slightly smaller, though still important, effects. Given her obesity, weight loss is the most impactful single intervention.
A 66-year-old woman with peripheral artery disease was started on atorvastatin 40 mg daily one month ago. She presents today with diffuse muscle aches and weakness, primarily in her thighs and shoulders, which began two weeks after starting the medication. Her creatine kinase (CK) level is normal. The symptoms resolved within a week of discontinuing atorvastatin.
Which of the following is the most appropriate next step in management?
Explanation: This patient is experiencing statin-associated muscle symptoms (SAMS). Given her history of peripheral artery disease, she is at very high risk for cardiovascular events and derives a significant benefit from statin therapy. The recommended approach for SAMS is to stop the initial statin, wait for symptoms to resolve, and then re-challenge with a different statin, often at a lower dose or with a different dosing schedule. Rosuvastatin is a hydrophilic statin and may be better tolerated. Starting at a low dose (5 mg) is a safe and appropriate strategy.
A 68-year-old man presents with a 6-month history of cramping pain in his right calf that occurs with walking and is relieved by rest. His ankle-brachial index is 0.65 on the right. He has no prior history of coronary artery disease or stroke. His fasting LDL cholesterol is 140 mg/dL.
In addition to smoking cessation and an exercise program, which medication is most important to initiate for secondary prevention of cardiovascular events?
Explanation: This patient has symptomatic peripheral artery disease (PAD), which is a form of atherosclerotic cardiovascular disease (ASCVD). Patients with clinical ASCVD are at very high risk for future cardiovascular events, including myocardial infarction and stroke. Guideline-directed medical therapy for all patients with PAD includes high-intensity statin therapy (e.g., atorvastatin 40-80 mg or rosuvastatin 20-40 mg) to lower LDL cholesterol by at least 50%, regardless of the baseline LDL level. Cilostazol is for symptom management (claudication) and does not prevent cardiovascular events.
A 54-year-old man with a BMI of 29 kg/m² and hyperlipidemia wants to improve his cardiovascular health. He has a sedentary job and exercises infrequently. He asks for a specific recommendation on physical activity.
Which of the following is the most appropriate initial weekly exercise goal for cardiovascular risk reduction?
Explanation: The American Heart Association and US guidelines recommend that adults should engage in at least 150 minutes per week of moderate-intensity aerobic physical activity or 75 minutes per week of vigorous-intensity aerobic activity (or an equivalent combination) for substantial health benefits. For a sedentary individual, starting with a goal of 150 minutes of moderate-intensity activity (e.g., 30 minutes, 5 days a week of brisk walking) is a standard and achievable initial recommendation.
A 63-year-old woman with a history of type 2 diabetes and stage 4 chronic kidney disease (eGFR 28 mL/min/1.73 m²), not on dialysis, presents for management. She has no known history of ASCVD. Her fasting LDL cholesterol is 160 mg/dL.
Which of the following is the most appropriate lipid-lowering therapy for this patient?
Explanation: For patients aged >50 with chronic kidney disease (CKD) not treated with dialysis, guidelines recommend treatment with a statin or a statin/ezetimibe combination. Due to the altered metabolism and increased risk of myopathy in patients with severe CKD, initiation of high-intensity statins is generally avoided. A moderate-intensity statin, such as atorvastatin 10-20 mg, is the recommended approach. Gemfibrozil should not be used with statins due to a high risk of myopathy.
A 52-year-old woman is evaluated for primary prevention of cardiovascular disease. Her 10-year ASCVD risk is calculated to be 9%, placing her in the borderline/intermediate risk category. She is hesitant to start a statin due to concerns about side effects. You discuss further risk stratification. She undergoes a coronary artery calcium (CAC) scan, which shows a score of 0.
Based on this new information, what is the most appropriate recommendation?
Explanation: In intermediate-risk patients (ASCVD risk 7.5% to <20%) who are uncertain about starting a statin, a CAC score can be a useful tool for shared decision-making. A CAC score of 0 indicates a very low burden of coronary atherosclerosis and a lower-than-expected short-term cardiovascular risk. In such cases, it is reasonable to withhold statin therapy and continue to focus on lifestyle modifications, with a plan to reassess risk in 5 to 10 years. This approach avoids unnecessary medication in a lower-risk individual.
A 70-year-old man is brought to the emergency department with a 45-minute episode of left-sided facial droop and garbled speech that completely resolved prior to arrival. His medical history is significant for hypertension. His non-contrast head CT is negative for acute hemorrhage. Carotid duplex ultrasound reveals a 75% stenosis of the right internal carotid artery.
Which of the following medical therapies is most critical to initiate immediately for secondary prevention of stroke?
Explanation: This patient has experienced a transient ischemic attack (TIA), which is an atherosclerotic cardiovascular disease event. Immediate initiation of antiplatelet therapy (aspirin) and high-intensity statin therapy is crucial for secondary stroke prevention, regardless of the patient's baseline LDL cholesterol. Dual antiplatelet therapy with aspirin and clopidogrel (not ticagrelor) may be considered for a short duration (21-90 days) for minor stroke or high-risk TIA, but aspirin and a high-intensity statin are the core initial components.
A 68-year-old man with a 30 pack-year smoking history, type 2 diabetes, and hypertension presents for his annual exam. He has no personal history of myocardial infarction, stroke, or peripheral artery disease. His 10-year ASCVD risk is calculated to be 30%. His blood pressure is 135/85 mmHg and his LDL cholesterol is 145 mg/dL.
Which of the following is the most appropriate intervention for primary prevention of atherosclerotic cardiovascular disease in this patient?
Explanation: This patient is at high risk for a primary ASCVD event, with a calculated 10-year risk of 30% (>20%). Current guidelines strongly recommend initiating high-intensity statin therapy for such individuals. Rosuvastatin 20 mg is a high-intensity statin. Ezetimibe is not a first-line agent for primary prevention. The use of aspirin for primary prevention is a more nuanced decision involving a discussion of risks and benefits and is not the most critical initial intervention. Clopidogrel is not indicated for primary prevention.
A 45-year-old man with type 2 diabetes and a BMI of 34 kg/m² is found to have a fasting triglyceride level of 750 mg/dL on a routine lipid panel. His LDL is 130 mg/dL and HDL is 28 mg/dL. He reports occasional, mild epigastric discomfort but denies acute, severe pain.
In addition to lifestyle modifications, which of the following is the most immediate therapeutic goal?
Explanation: While managing all aspects of this patient's dyslipidemia is important for long-term ASCVD risk reduction, severe hypertriglyceridemia (typically defined as >500 mg/dL) poses a significant short-term risk of acute pancreatitis. Therefore, the most immediate goal is to lower triglyceride levels. This is typically achieved with fibrate therapy (e.g., fenofibrate), high-dose omega-3 fatty acids, and aggressive lifestyle changes, including strict dietary fat restriction and glycemic control. Once triglycerides are lowered, attention can be more focused on LDL cholesterol.
A 60-year-old man with newly diagnosed hypertension is receiving lifestyle counseling. His current diet is high in sodium, saturated fats, and red meat, with few fruits and vegetables. His blood pressure is 148/92 mmHg.
Which of the following dietary patterns is most strongly recommended for lowering blood pressure and reducing cardiovascular risk?
Explanation: The Dietary Approaches to Stop Hypertension (DASH) diet is a well-established dietary pattern proven to lower blood pressure and reduce cardiovascular risk. It emphasizes fruits, vegetables, whole grains, and low-fat dairy products while limiting intake of sodium, saturated fat, cholesterol, and red meat. It has been shown to lower systolic blood pressure by 8-14 mmHg, an effect comparable to some first-line antihypertensive medications. The other diets listed do not have the same level of evidence for blood pressure reduction.
A 59-year-old woman is discharged from the hospital after successful percutaneous coronary intervention with a drug-eluting stent for an ST-elevation myocardial infarction. Her discharge medications include aspirin 81 mg, ticagrelor 90 mg twice daily, atorvastatin 80 mg, and lisinopril 10 mg.
What is the most appropriate recommendation regarding the duration of her antiplatelet therapy?
Explanation: After an acute coronary syndrome (ACS) treated with a drug-eluting stent, dual antiplatelet therapy (DAPT) with aspirin and a P2Y12 inhibitor (like ticagrelor or clopidogrel) is indicated to prevent stent thrombosis and recurrent ischemic events. The standard duration for DAPT is at least 12 months. After this period, aspirin is typically continued indefinitely for secondary prevention. The P2Y12 inhibitor may be stopped or continued depending on the patient's ischemic versus bleeding risk.
A 69-year-old man with stable ischemic heart disease requires long-term antiplatelet therapy for secondary prevention. He has a documented history of a true IgE-mediated allergy to aspirin, which caused urticaria and angioedema. He is currently taking metoprolol and atorvastatin.
Which of the following is the most appropriate long-term monotherapy for this patient?
Explanation: For patients with established ASCVD who require antiplatelet therapy for secondary prevention but have a contraindication or true allergy to aspirin, a P2Y12 inhibitor such as clopidogrel is the recommended alternative for long-term monotherapy. Ticagrelor is typically used as part of dual antiplatelet therapy for a limited duration after an acute coronary syndrome. Warfarin and apixaban are anticoagulants and are not indicated as substitutes for antiplatelet therapy in this setting unless there is a concurrent indication, such as atrial fibrillation.